dr. siefker-radtke on the treatment of fgfr-altered bladder cancer
Published 5 years ago • 63 plays • Length 1:51Download video MP4
Download video MP3
Similar videos
-
1:54
dr. siefker-radtke on the phase ii study of erdafitinib in patients with urothelial carcinoma
-
0:57
dr. siefker-radtke on next steps with erdafitinib in bladder cancer
-
0:38
dr. siefker-radtke on fda approval of avelumab in bladder cancer
-
0:55
dr. siefker-radtke on fda approval of frontline atezolizumab in bladder cancer
-
0:53
dr. siefker-radtke on fda approval of durvalumab in bladder cancer
-
1:19
dr. siefker-radtke on advancements in small cell urothelial cancer
-
4:42
arlene siefker-radtke, md, regarding the development of erdafitinib in bladder cancer
-
1:47
dr. siefker-radtke on pd-l1 as a biomarker in bladder cancer
-
1:59
arlene siefker-radtke, md, on how new data will impact treatment of neoadjuvant bladder cancer
-
4:11
an overview of targeted fgfr3 therapy in bladder cancer with dr. siefker-radtke
-
0:45
prof. siefker-radtke on the ev-103 trial in bladder cancer
-
11:07
drs. siefker-radtke, koshkin on the norse study for metastatic urothelial carcinoma
-
2:04
unmet need in bladder cancer
-
1:28
erdafitinib for bladder cancer: more to come following fda approval
-
8:43
fda approvals in bladder cancer and nsclc, and 2019 elcc highlights
-
12:14
the latest in bladder cancer with fgfr 2 and 3 mutations
-
1:03
dr. sklar on the role of nivolumab in bladder cancer
-
2:52
fgfri treatment-emergent aes in urothelial cancer
-
1:15
dr. iyer on challenges with selecting patients with bladder cancer for fgfr inhibitors